Spinal Fusion Lumbar denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for spinal fusion lumbar are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Lumbar Spinal Fusion as "Not FDA-Approved" — and How to Challenge It

Lumbar spinal fusion as a surgical procedure category is well-established and performed using FDA-cleared devices and instrumentation. A "not FDA-approved" denial for spinal fusion typically means Cigna has determined that a specific device, implant, bone graft product, or surgical technique used during the procedure lacks FDA clearance or approval for the specific indication, or that an emerging minimally invasive approach has not yet received the same level of regulatory recognition as its open surgical counterpart. Understanding exactly which element Cigna is challenging is the first and most critical step.

## Why This Denial Is Appealable

ACA §2719 requires that clinical or experimental-type denials be eligible for independent external review. ERISA §503 provides the full-and-fair review requirement. The external review window is generally approximately four months from the adverse determination notice — confirm the exact deadline on your EOB. If delay creates serious risk of harm (e.g., progressive neurological compromise), expedited review is available.

Importantly, FDA clearance via the 510(k) pathway — which applies to most spinal surgical devices — is legally sufficient for insurance coverage purposes, even though it is distinct from full FDA approval (PMA). If Cigna is conflating these, that is a specific, correctable error.

## Concrete Appeal Process

1. Request the denial in full writing — identify exactly which device, material, implant, or surgical technique Cigna has classified as not FDA-approved. 2. Obtain FDA clearance records — work with the device manufacturer or the operating surgeon's office to compile 510(k) clearance letters, PMA approvals, or Humanitarian Device Exemption (HDE) documentation, confirming the regulatory status of every component at issue. 3. Document the labeled indication — confirm that the device was used within its FDA-cleared indication for use; if it was used off-label, the surgeon's letter should address why this use reflects the accepted standard of care. 4. File a Level 1 internal appeal with FDA documentation and a surgeon's letter. 5. Escalate to external review if Level 1 is upheld.

## Documentation to Gather

• FDA 510(k) clearance or PMA approval: For each device or implant at issue, the official FDA clearance letter specifying the indication for use.
• Operative report: A detailed surgical report identifying every device and material used, by manufacturer and catalog number, allowing cross-reference to regulatory records.
• Surgeon's medical necessity letter: A statement explaining the clinical rationale for selecting each component, confirming use within the cleared indication, and — if any off-label use occurred — citing the clinical evidence and professional society endorsement supporting that use.
• Imaging and diagnosis records: Pre-operative studies confirming the structural pathology and surgical indication.
• Conservative treatment history: Documentation that appropriate non-surgical management was tried and failed, supporting the overall medical necessity of surgery.

## Criteria-Mapping Structure

Request Cigna's coverage policy for spinal fusion and its technology assessment for the specific device or technique at issue. For each basis cited in the denial — lack of FDA clearance, off-label use, insufficient evidence for the indication — supply the specific regulatory document or clinical citation that addresses it directly. A surgeon's peer-to-peer call with Cigna's medical director, concurrent with the Level 1 appeal, is particularly valuable when the denial rests on a regulatory mischaracterization.